Cytokinetics, Incorporated Contracts & Agreements

188 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED (As amended by the Board of Directors on February 6, 2013; Stockholder approval May 22, 2013; updated following...
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
2013
Employment Offer Letter between Cytokinetics, Incorporated and Brett Pletcher
Employment Agreements
Cytokinetics, Incorporated
2024
Sixth Amendment to Lease, dated July 30, 2024, by and between KR Oyster Point 1, LLC, and Cytokinetics, Incorporated
Lease Agreements
Cytokinetics, Incorporated
2024
Employment Offer Letter between Cytokinetics, Incorporated and Sung H. Lee
Employment Agreements
Cytokinetics, Incorporated
2024
Third Amendment, dated May 22, 2024, to Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company
Loan Agreements
Cytokinetics, Incorporated
2024
Amendment No. 1, dated May 22, 2024, to Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between Royalty Pharma Investments 2019 ICAV and the Company
Purchase Agreements
Cytokinetics, Incorporated
2024
2024 Development Funding Loan Agreement, dated May 22, 2024, by and among Royalty Pharma Development Funding, LLC and the Company
Loan Agreements
Cytokinetics, Incorporated
2024
CK-586 Revenue Participation Right Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company
Purchase Agreements
Cytokinetics, Incorporated
2024
Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company
Stock Agreements
Cytokinetics, Incorporated
2024
Underwriting Agreement, dated as of May 22, 2024, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC
Underwriting Agreements
Cytokinetics, Incorporated
2024
Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan
Stock Agreements
Cytokinetics, Incorporated
2024
Description of Director Compensation
Compensation Agreements
Cytokinetics, Incorporated
2024
Form of Performance Stock Unit Award Agreement
Bonus & Incentive Agreements
Cytokinetics, Incorporated
2024
Fifth Amendment to Lease, dated November 27, 2023, by and between the Company and KR Oyster Point 1, LLC
Lease Agreements
Cytokinetics, Incorporated
2024
Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description
Severance Agreements
Cytokinetics, Incorporated
2023
Description of Director Compensation
Compensation Agreements
Cytokinetics, Incorporated
Biotechnology
2022
Indenture, dated as of July 6, 2022, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee
Indenture Agreements
Cytokinetics, Incorporated
2022
Third Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC
Lease Agreements
Cytokinetics, Incorporated
Biotechnology
2022
License and Collaboration Agreement, dated December 20, 2021, by and between the Company and Ji Xing Pharmaceuticals Limited
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2022
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Master Fund, Ltd
Stock Agreements
Cytokinetics, Incorporated
2022
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Innovation Master Fund, Ltd
Stock Agreements
Cytokinetics, Incorporated
2022
Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Venture Fund Limited
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2022
Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company
Loan Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2022
Amendment No. 1 to Royalty Purchase Agreement, dated January 7, 2022, by and between the Company and RPI Finance Trust
Purchase Agreements
Cytokinetics, Incorporated
Biotechnology
2022
Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between the Company and Royalty Pharma Investments 2019 ICAV
Purchase Agreements
Cytokinetics, Incorporated
2022
Fourth Amendment to Loan and Security Agreement, dated June 30, 2021, by and among the Company, Oxford Finance LLC and Silicon Valley Bank
Loan Agreements
Cytokinetics, Incorporated
Biotechnology
2021
Amended and Restated 2004 Equity Incentive Plan
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2021
Eighth Amendment to Lease, dated May 18, 2021, by and between the Company and Britannia Pointe Grand Limited Partnership
Lease Agreements
Cytokinetics, Incorporated
2021
Underwriting Agreement, dated as of July 20, 2021, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC
Underwriting Agreements
Cytokinetics, Incorporated
Biotechnology
2021
First Amendment to Lease, dated May 12, 2020, by and between the Company and KR Oyster Point 1, LLC
Lease Agreements
Cytokinetics, Incorporated
2021
Second Amendment to Lease, dated January 26, 2021, by and between the Company and KR Oyster Point 1, LLC
Lease Agreements
Cytokinetics, Incorporated
2021
Letter Agreement, dated December 23, 2020, by and between Company and Astellas amending the License and Collaboration Agreement for Other Skeletal Sarcomere Activators, dated...
Collaboration Agreements
Cytokinetics, Incorporated
2021
License and Collaboration Agreement, dated July 14, 2020, by and between the Company and Ji Xing Pharmaceuticals Limited
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2020
Funding Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company
Funding Agreements
Cytokinetics, Incorporated
2020
Royalty Purchase Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company
Purchase Agreements
Cytokinetics, Incorporated
2020
Form of Common Stock Purchase Agreement, dated July 14, 2020
Stock Agreements
Cytokinetics, Incorporated
2020
Third Amendment to Loan and Security Agreement, dated July 16, 2020, by and among the Company, Oxford Finance LLC and Silicon Valley Bank
Loan Agreements
Cytokinetics, Incorporated
Biotechnology
2020
Fast Skeletal Regulatory Activator Agreement, dated April 23, 2020, by and between the Company and Astellas Pharma Inc
Cytokinetics, Incorporated
2020
Underwriting Agreement, dated as of July 16, 2020, by and among Cytokinetics, Incorporated, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co
Underwriting Agreements
Cytokinetics, Incorporated
Biotechnology
2020
Description of Securities
Cytokinetics, Incorporated
Biotechnology
2020
Compensation Information for the Companys Named Executive Officers
Compensation Agreements
Cytokinetics, Incorporated
2020
Underwriting Agreement, dated November 7, 2019, by and between the Company and Morgan Stanley & Co. LLC as representative of the several underwriters named therein
Underwriting Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2019
Base Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee
Indenture Agreements
Cytokinetics, Incorporated
2019
First Supplemental Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (including the form of 4.00% Convertible Senior Note due...
Indenture Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2019
First Amendment to Loan and Security Agreement, dated as of November 6, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank
Loan Agreements
Cytokinetics, Incorporated
Biotechnology
2019
Second Amendment to Loan and Security Agreement, dated as of November 7, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank
Loan Agreements
Cytokinetics, Incorporated
2019
Seventh Amendment to Lease, dated July 11, 2019, by and between the Company and Britannia Pointe Grand Limited Partnership
Lease Agreements
Cytokinetics, Incorporated
Biotechnology
2019
Form of Warrant Issuable to Oxford Finance LLC
Warrant Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2019
Form of Warrant Issuable to Silicon Valley Bank
Warrant Agreements
Cytokinetics, Incorporated
2019
Loan and Security Agreement, dated as of May 17, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank
Loan Agreements
Cytokinetics, Incorporated
2019
Controlled Equity Offering Sales Agreement, dated as of March 6, 2019, by and between the Company and Cantor Fitzgerald & Co
Sales Agreements
Cytokinetics, Incorporated
2019
Amendment No. 8, dated November 30, 2016, to the Collaboration and Option Agreement by and between the Company and Amgen Inc
Collaboration Agreements
Cytokinetics, Incorporated
2019
Amendment No. 9, dated February 6, 2019, to the Collaboration and Option Agreement by and between the Company and Amgen Inc
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
2019
Amendment to Collaboration Agreement; Joint Development Committee Membership
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
2018
Second Amendment to Loan and Security Agreement by and among the Company, Oxford Finance LLC and Silicon Valley Bank, dated as of October 27, 2017
Loan Agreements
Cytokinetics, Incorporated
Biotechnology
2018
Fifth Amendment to Lease, dated December 18, 2017, by and between the Company and Britannia Pointe Grand Limited Partnership
Lease Agreements
Cytokinetics, Incorporated
2018
Amendment to Collaboration Agreement between the Company and Astellas Pharma Inc., dated December 21, 2017
Collaboration Agreements
Cytokinetics, Incorporated
2018
Compensation Information for the Companys Named Executive Officers
Compensation Agreements
Cytokinetics, Incorporated
Biotechnology
2018
Controlled Equity OfferingSM Sales Agreement, dated November 3, 2017, by and between Cytokinetics, Incorporated and Cantor Fitzgerald & Co
Sales Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2017
Amended and Restated 2004 Equity Incentive Plan
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2017
Exhibit
Cytokinetics, Incorporated
Biotechnology
2017
5,260,000Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT
Underwriting Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2017
ROYALTYPURCHASE AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND RPIFINANCE TRUST DATED AS OF FEBRUARY 1, 2017 TABLE OF CONTENTS
Trust Agreements
Cytokinetics, Incorporated
2017
CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2017
Compensation Information for Named Executive Officers
Compensation Agreements
Cytokinetics, Incorporated
Biotechnology
2017
AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT
Collaboration Agreements
Cytokinetics, Incorporated
2016
LETTEROF AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND AMGEN INC. AND LES LABORATOIRES SERVIER AND INSTITUT DERECHERCHES INTERNATIONALES SERVIER DATED AUGUST 29, 2016
Cytokinetics, Incorporated
2016
FOURTH AMENDMENT TO BUILD TO SUIT LEASE
Lease Agreements
Cytokinetics, Incorporated
2016
WARRANT TO PURCHASESTOCK
Warrant Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2016
LOAN ANDSECURITY AGREEMENT
Loan Agreements
Cytokinetics, Incorporated
2016
Compensation Information for Named Executive Officers
Compensation Agreements
Cytokinetics, Incorporated
Biotechnology
2016
CYTOKINETICS, INCORPORATED Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2015
CYTOKINETICS, INCORPORATED AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN AMENDED BY THE BOARD OF DIRECTORS:FEBRUARY 6, 2013 APPROVED BY STOCKHOLDERS:MAY 22, 2013 AMENDED TO...
Bonus & Incentive Agreements
Cytokinetics, Incorporated
2015
CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS:MAY 20, 2015 EFFECTIVE DATE: NOVEMBER...
Stock Agreements
Cytokinetics, Incorporated
2015
AMENDMENT NO. 7 TO COLLABORATION AND OPTION AGREEMENT
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
2015
Amended andRestated License and Collaboration Agreement by and between Cytokinetics, Inc. and Astellas Pharma Inc.
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2015
Compensation Information for Named Executive Officers
Compensation Agreements
Cytokinetics, Incorporated
Biotechnology
2015
CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2014
CYTOKINETICS, INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Cytokinetics, Incorporated
2014
2013 Bonus and 2014 Compensation Information for Named Executive Officers
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
2014
4,375,000 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT
Underwriting Agreements
Cytokinetics, Incorporated
2014
CYTOKINETICS, INCORPORATED 2004 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on February 6, 2013; stockholder approval May 22, 2013; updated following...
Purchase Agreements
Cytokinetics, Incorporated
2013
AMENDMENT NO. 6 TO COLLABORATION AND OPTION AGREEMENT
Collaboration Agreements
Cytokinetics, Incorporated
Biotechnology
2013
License andCollaboration Agreement by and between Cytokinetics, Inc. and Astellas Pharma Inc.
License Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2013
CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2013
CYTOKINETICS, INCORPORATED 2004 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on March 15, 2006 and approved by the Stockholders May 25, 2006, asamended by...
Stock Agreements
Cytokinetics, Incorporated
2013
AMENDMENT NO. 2 TO CONSULTING AGREEMENT
Consulting Agreements
Cytokinetics, Incorporated
2013
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED FORM OF OPTION AGREEMENT
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2013
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
2013
2012 Bonus and 2013 Compensation Information for Named Executive Officers
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
2013
Warrant to Purchase Common Stock of Cytokinetics, Incorporated
Warrant Agreements
Cytokinetics, Incorporated
2012
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN, AS AMENDED
Bonus & Incentive Agreements
Cytokinetics, Incorporated
Biotechnology
2012
55,921,055 Shares of Common Stock Warrants to Purchase 33,552,633 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT
Underwriting Agreements
Cytokinetics, Incorporated
2012
23,026 Shares of Series B Convertible PreferredStock Warrants to Purchase 13,815,600 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT
Underwriting Agreements
Cytokinetics, Incorporated
2012
CYTOKINETICS, INCORPORATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE...
Stock Agreements
Cytokinetics, Incorporated
2012
Warrant to Purchase Common Stock of Cytokinetics, Incorporated
Warrant Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2012
AMENDMENT NO. 1 TO CONSULTING AGREEMENT
Consulting Agreements
Cytokinetics, Incorporated
Biotechnology
2012
CYTOKINETICS, INC. CONSULTING AGREEMENT
Consulting Agreements
Cytokinetics, Incorporated
Biotechnology
CA
2012
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT
Bonus & Incentive Agreements
Cytokinetics, Incorporated
2011
EX-101 INSTANCE DOCUMENT
Cytokinetics, Incorporated
Biotechnology
2011
CYTOKINETICS, INCORPORATED
Cytokinetics, Incorporated
Biotechnology
NY
2011
CYTOKINETICS, INCORPORATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE...
Stock Agreements
Cytokinetics, Incorporated
2011
SECURITIES PURCHASE AGREEMENT
Purchase Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2011
Warrant to Purchase Common Stock of Cytokinetics, Incorporated
Warrant Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2011
guidance concerning revenues, research and development expenses and general and administrative expenses for 2011
Development Agreements
Cytokinetics, Incorporated
2011
guidance concerning revenues, research and development expenses and general and administrative expenses for 2011
Development Agreements
Cytokinetics, Incorporated
Biotechnology
2011
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
2010
Current assets
Cytokinetics, Incorporated
2010
guidance concerning revenues, research and development expenses and general and administrative expenses for 2010
Development Agreements
Cytokinetics, Incorporated
Biotechnology
2010
Current assets
Cytokinetics, Incorporated
2009
Current assets
Cytokinetics, Incorporated
Biotechnology
2009
Current assets
Cytokinetics, Incorporated
Biotechnology
2009
Current assets
Cytokinetics, Incorporated
Biotechnology
CT
2009
7,106,600 Shares of Common Stock and Warrants to Purchase up to 3,553,300 Shares of Common Stock CYTOKINETICS, INCORPORATED PLACEMENT AGENT AGREEMENT
Stock Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2009
SUBSCRIPTION AGREEMENT
Subscription Agreements
Cytokinetics, Incorporated
2009
CYTOKINETICS, INCORPORATED WARRANT TO PURCHASE COMMON STOCK
Warrant Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
Biotechnology
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
Biotechnology
NY
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
2009
guidance concerning revenues, research and development expenses and general and administrative expenses for 2009
Development Agreements
Cytokinetics, Incorporated
Biotechnology
2009
Current assets
Cytokinetics, Incorporated
2008
Current assets
Cytokinetics, Incorporated
2008
Current assets
Cytokinetics, Incorporated
2008
Current assets
Cytokinetics, Incorporated
2008
GlaxoSmithKline 2301 Renaissance Boulevard Building #510RN0420 King of Prussia, Pennsylvania 19406 Attn: Vinod Ramachandran, Ph.D.
Cytokinetics, Incorporated
2008
GlaxoSmithKline 2301 Renaissance Boulevard Building #510RN0420 King of Prussia, Pennsylvania 19406 Attn: Vinod Ramachandran, Ph.D.
Cytokinetics, Incorporated
2008
CYTOKINETICS, INCORPORATED 2004 EQUITY INCENTIVE PLAN (as amended and restated as of May 22,2008)
Bonus & Incentive Agreements
Cytokinetics, Incorporated
2008
CYTOKINETICS, INC. SCIENTIFIC ADVISORY BOARD CONSULTING AGREEMENT
Consulting Agreements
Cytokinetics, Incorporated
2008
CYTOKINETICS, INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Cytokinetics, Incorporated
2008
WARRANT
Warrant Agreements
Cytokinetics, Incorporated
2007
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreements
Cytokinetics, Incorporated
2007
GlaxoSmithKline2301 Renaissance BoulevardBuilding #510RN0420King of Prussia, Pennsylvania 19406 Attn: Scott Klesmer
Cytokinetics, Incorporated
2007
CYTOKINETICS, INCORPORATED AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Cytokinetics, Incorporated
2007
Current assets
Cytokinetics, Incorporated
2007
the initiation, progress, timing, scope and anticipated date of completion of clinical trials and development for our drug candidates and potential drug candidates by ourselves,...
Development Agreements
Cytokinetics, Incorporated
2007
CYTOKINETICS, INCORPORATED
Cytokinetics, Incorporated
2007
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreements
Cytokinetics, Incorporated
2007
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Current assets
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
the initiation, progress, timing, scope and anticipated date of completion of preclinical research, clinical trials and development for our drug candidates and potential drug...
Development Agreements
Cytokinetics, Incorporated
2006
Name and Title
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Exhibit No
Cytokinetics, Incorporated
2006
Sublease, dated as of November 29, 2005, by and among the Company and the parties named therein
Lease Agreements
Cytokinetics, Incorporated
2005
CYTOKINETICS,INCORPORATED EXECUTIVE EMPLOYMENT AGREEMENT
Employment Agreements
Cytokinetics, Incorporated
2005
Current assets
Cytokinetics, Incorporated
2005
Current assets
Cytokinetics, Incorporated
2005
Current Assets
Cytokinetics, Incorporated
2005
Amendment No. 2 To Collaboration Agreement
Collaboration Agreements
Cytokinetics, Incorporated
2005
Current Assets
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Current Assets
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid...
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid...
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid...
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid...
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004
Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid
Cytokinetics, Incorporated
2004